Clinical Trials Browser

Phase 2 × INDUSTRY × Albumin-Bound Paclitaxel × Clear all

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT07483554 2026-03-19

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

Phase 2 Not yet recruiting

389 enrolled

Gastrointestinal

CLDN18.2 Positive

NCT06731907 2026-02-18

MK-3475-01G

Phase 2 Recruiting

90 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04770272 2026-01-12

neoMono

Phase 2 Terminated

442 enrolled 42 charts

Breast

Triple Negative Breast Neoplasms

NCT04958785 2025-11-04

ELEVATE TNBC

Phase 2 Terminated

92 enrolled 27 charts

Breast

Triple Negative Breast Neoplasms

Clinical Trials

9-ING-41 in Patients With Advanced Cancers

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

MK-3475-01G

neoMono

ELEVATE TNBC

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

KEYVIBE-005

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer

abound2L+

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Saltikva for Metastatic Pancreatic Cancer

MARIO-3

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

PGPC1

HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy

A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC

YOSEMITE

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer

Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer

First Line Therapy for Patients With Metastatic Breast Cancer

Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer

An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin

Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer

LAPACT

GSK1120212 Rollover Study

Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies

AboundPS2

CARRIE

NEFERTT

PANC-001

Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma

ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer

Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma

Phase II Study of ABI-007 for Gastric Cancer